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ther consider changes in societal structure. Dr Towne will
address this issue from the perspective of the SVS in his pres-
idential address later at this meeting. For the North
American Chapter, your council proposes a change in our
name to the American Association for Vascular Surgery
(AAVS) while retaining our chapter relationship to the
ISCVS. One of the important reasons is to enhance our
identity with HCFA and other governmental agencies as a
truly North American Society. We wish to focus the activities
of the AAVS specifically on the needs of the practicing vas-
cular surgeon. As such, we propose the AAVS serve as an
umbrella organization accommodating the leading regional
and national vascular societies of which many, if not most, of
you are already members. We propose that each of these
societies have a voting membership on the council of the
new organization. The AAVS will, in effect, belong to the
practicing vascular surgeons in this country.
At the recent meeting of the Strategic Planning
Committee, it was recommended that we maintain two soci-
eties and that the AAVS have primary responsibility for gov-
ernmental relations, especially as it concerns reimbursement
issues, and with public education. We will participate with
the SVS in maintaining an association with other groups car-
ing for patients with vascular disease, including the Society
for Cardiovascular and Interventional Radiology, the
American College of Cardiology, the Society for Vascular
Medicine and Biology, and others.
As a professional society, we are light-years behind simi-
lar organizations in informing the lay public of basic infor-
mation concerning the diseases and conditions we treat. The
remarkable accessibility of the Internet to our population
provides a readily available site for the dissemination of infor-
mation. I am sure most of you are already receiving calls
from patients wanting to discuss confusing material they
have received on the Internet, much of which presently can
be best described as self-serving baloney placed for purely
commercial reasons. Clearly, we have an extraordinary
opportunity to develop and disseminate to the public an
accurate description of vascular disease and realistic expecta-
tions from vascular surgery. The AAVS intends to forge
ahead on this front without delay.
The AAVS recommends assigning primary responsibil-
ity for a number of important activities to the SVS includ-
ing management of relations with the American Board of
Surgery (ABS), the Association of Program Directors in
I am honored to address you as the 44th president of
the North American Chapter of the International Society
for Cardiovascular Surgery (ISCVS), on this the occasion of
our 48th annual chapter meeting. The winds of change are
sweeping our society, and to place these changes into per-
spective requires a consideration of our history. The first
meeting of the then-designated International Society of
Angiology was held in 1951, and the first meeting of the
North American Chapter in 1952. In 1957, the name of the
society was changed to the International Cardiovascular
Society, and in 1981 changed again to the International
Society for Cardiovascular Surgery. We held a combined
meeting with the Society for Vascular Surgery (SVS) for the
first time in 1967. An increasing realization of the common
issues facing the societies led to the formation and the first
meeting of the Joint Council in 1975. For the next 25 years,
the two societies grew together to the point where there is
presently little to choose between them, because both are
run by the Joint Council, which has assumed, for all practi-
cal purposes, total managerial control.
Since its formation, the Society for Cardiovascular
Surgery has increased internationally from three to seven
chapters with a commensurate increase in membership. As of
1999, membership in the International stood at almost
3800, of which 1650 were from our North American
Chapter. The last biannual meeting of the International took
place in September 1999, in Melbourne, and the 50th
anniversary of our North American Chapter will be observed
during our annual meeting in Boston 2 years hence.
During the past year there has been a growing belief
among the councils of the SVS and ISCVS that either there
should be a real difference between the two societies or we
should consider combining into a single society. After much
preliminary planning, a retreat was held in New Orleans in
February 2000 to discuss this and other topics, and a meet-
ing of the Strategic Planning Group was recently held to fur-
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Vascular Surgery, the Residency Review Committee in
Surgery, and the Lifeline Foundation. Clearly, however, the
AAVS will maintain a keen interest in following and partic-
ipating in these activities as appropriate. We will continue to
jointly administer the Journal of Vascular Surgery and the
annual meeting, although more precise program separation
will likely occur in the future. We will continue to share with
the SVS the responsibility for nominations to the ABS and
will, of course, continue with our periodic appointment to
the Sub-board in Vascular Surgery. We recommend that, in
effect, the joint council model of societal governance be
substantially reduced or eliminated, with each society
assuming independent responsibility for a designated group
of critical functions. These proposed changes will be sub-
mitted to the membership for approval in the near future.
I believe these structural societal changes will benefit our
membership by substantially eliminating the redundant gov-
ernance structure that has characterized us in recent decades
and will permit a more precise direction of our attention to
specific areas of interest. In the case of the AAVS, this will
permit an intense focus on the needs of the practicing vascu-
lar surgeon. I express my appreciation and admiration to the
members of both societies who are in the process of accom-
plishing these important structural changes and are devoting
large amounts of time and effort to this activity. A commit-
tee of AAVS members headed by Dr William Pearce is cur-
rently addressing the issue of AAVS reorganization, and I
express my appreciation to him and his committee for
accepting this important assignment.
It is traditional for the president, on the occasion of
the annual address, to recognize those who have been of
special importance to his career development. I proudly
continue this worthy tradition. First, I acknowledge with
profound appreciation the contributions of my wife, Ann,
who combined her own university graduate education
with full-time employment and motherhood, while hold-
ing the family together during an enjoyable, but occasion-
ally tumultuous 9-year surgical residency. I guess it just
took me longer than most.
I have spent my entire career in Academic Vascular
Surgery and am pleased to recognize the contributions of
the four distinguished surgical chairmen under whom I have
been privileged to serve (Figure). During my residency at
Duke, I received wise and much appreciated counsel from
my first chairman, Dr Clarence E. Gardner, and later from
Dr David C. Sabiston, Jr. In my early faculty career at
Oregon, Dr William W. Krippaehne provided abundant sup-
port, and most recently, I am pleased to acknowledge the
considerable assistance received from Dr Donald D.
Trunkey, who has been most supportive of the development
of our Academic Vascular Surgery unit.
Two additional professors who had a critical influence on
my early career were Dr Keith S. Grimson, now deceased,
professor of surgery at Duke and a true pioneer in the excit-
ing new field of vascular surgery, and Dr Donald Silver, then
a professor of surgery at Duke, who provided me a superb
model of academic discipline as well as an excellent laboratory
in which to work. I am honored to acknowledge the contri-
butions of these two gentlemen to my surgical education in
general and specifically to my decision to enter vascular
surgery. I am also pleased to recognize the contributions of
my senior faculty associate Dr Lloyd M. Taylor, Jr, who has
assisted me mightily in the development of our vascular
surgery unit at Oregon. In recent years I have had to tolerate
the irreverence of Dr Greg Moneta, which I must admit I
have come to accept with some fondness despite his Harvard
background. The assistance and loyalty of my other vascular
faculty associates, Drs Rich Yeager, James Edwards, and Greg
Landry, are gratefully acknowledged.
For the remainder of this address, I propose to make
observations on a group of topics that I believe are impor-
tant to vascular surgeons and the practice of vascular surgery.
In preparing these remarks I have carefully reviewed prior
presidential addresses and have concluded that they were
generally designed to accomplish one of several things: some
appeared designed to inform, some to motivate, and some to
inspire. As far as I can tell this is the first that may be per-
ceived as specifically designed to annoy, although I hasten to
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Surgical chairmen under whom your president has had the privilege of serving.
add annoyance for its own sake is hardly the objective. The
topics I have selected for consideration include Health Care
Financing, the Role of Functional Outcome Assessment in
Vascular Surgery, Residency Education Including Certifi-
cation in Vascular Surgery, and finally, my perception of the
pernicious influence of the new generation of Entrepreneur-
ialism in Vascular Surgery. 
HEALTH CARE FINANCING
Few topics have attracted and focused the attention of the
US Congress with greater zeal than the costs of health care in
America. They suddenly realized in the last decade that health
care costs in this county were approaching 14% of the GDP
and appeared to be rising exponentially. They looked forward
to doomsday when they envisioned the health care budget
consuming the entire federal budget and decided that dra-
conian measures were required to restrain health care
expenses. From the DRGs of the 1980s through RBRVS and
the most recently balanced budget amendments of the late
1990s, all their actions appeared uniquely disadvantageous to
vascular surgery. Their overall behavior led to the formulation
of my current opinion of Congress, succinctly summarized as
follows: Never underestimate the power of stupid people in
large groups. You are all aware of the many measures that
have resulted from the congressional attempts to control
health care expenditures. We were significantly underrepre-
sented in the Hsiao study, making us the last in line when the
RBRVS payment schedules were created. I express my deep
appreciation to Drs Hertzer, Trout, Zwolak, and Oblath and
their associates for the time and effort expended on our
behalf before HCFA and other governmental groups. They
have been able to reduce the rate of decrease in our mite and
may have even achieved a tiny increase. Nonetheless, for vas-
cular surgeons a terrible financial problem persists.
Reimbursement has decreased to the point where in many
parts of the country it is fiscally impossible to open a one-
surgeon office and enter the practice of vascular surgery.
Many vascular surgeons have taken early retirement, and oth-
ers are planning to do so. The number of trainees applying for
vascular residency positions is disturbingly low, doubtlessly
related in part to the trainees’ perception of reimbursement
matters. These issues threaten to have a significantly negative
impact on vascular surgery manpower.
I continue to be profoundly disturbed by the big picture
of health care financing. I accept that both England and
Canada seem to muddle through their health care needs with
expenditures of about 7% of the GDP, while presently, the
United States appears stuck at 13% to 14%; but, on the other
hand, consider for a moment what you get. With few excep-
tions today in America a patient needing hospital care can
expect immediate admission to a pleasant and modernly
equipped facility and receive generally expert care rendered
by a fully trained physician, none of which is available for 7%
of the GDP. I suspect the old adage is true: If you want nice
fresh oats, you have to pay a little more. Oats that have
already passed through the horse are available for a little less.
Keep in mind, one of the most important jobs of Congress,
if not the most important job, is budget prioritization. If the
citizens demand health care that costs 14% of the GDP or
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even 20%, this seems to me to be the citizens’ choice. We may
even, God forbid, have to forego another class of nuclear
attack submarines! Please do not misunderstand: I am not in
favor of bureaucratically inefficient health care delivery or the
knee-jerk purchase of billions of dollars of currently stylish
breakthrough equipment without meticulous justification.
Neither I nor anyone else can possibly object to improved
efficiencies in health care, but I can and do object to the sim-
plistic notion that national health care costs must conform to
a predetermined percentage of the GDP.
Another area that causes me much concern is the issue of
a physician’s choice of treatment having a direct effect on per-
sonal income. Surgeons are regularly required to make diffi-
cult choices between operative and nonoperative treatments,
each with profoundly different personal income implications.
I am not sure the Almighty herself could remain neutral in
such situations. We must strive for the day when a physician’s
therapeutic choices have no impact on physician income.
In my opinion, two shames of our present health care sys-
tem are first, the 45 million or so citizens of this county with
no provision at all for health care and second, the invasion of
health care delivery by for-profit organizations, typically
HMOs, whose primary objective is to divert as many finite
dollars as possible from their intended health care objectives
into corporate profits, including the salaries of obscenely well-
compensated CEOs. For the former I see no solution other
than providing a basic federally administered health care
insurance policy much like the Oregon Health Plan. We as a
nation are simply going to have to face the issue that we can
no longer ignore the health care needs of this significant per-
centage of our population. Piecemeal approaches are inade-
quate. As a great American once said: You cannot leap a
chasm in two jumps. I believe we must also provide brick and
mortar facilities where these citizens can receive basic well-
patient health care and that will serve as a convenient point of
entry into the health care system for sick patients.
These facilities can no doubt be adequately staffed in sig-
nificant part by nurse practitioners and physician assistants.
Numerous studies have shown that in outpatient clinics,
expensive primary care physicians are expendable. In fact,
producing more and more primary care physicians in a futile
effort to reduce health care costs appears to have been one
of the most conspicuously unsuccessful experiments of mod-
ern politicians. I am appalled to note that the Florida legisla-
ture has just approved funding for yet another General
Practice Medical School, this one at the Florida State
University. Sick patients require specialist care, and I suspect
always will. Whatever primary care physicians do can gener-
ally be done as well and cheaper by paramedical personnel.
In my opinion, about the last thing we need is another polit-
ically motivated GP medical school.
What about the for-profit HMOs? We probably need
not overly concern ourselves with these entrepreneurs.
They already appear to be imploding. Profits are dwin-
dling, federal fraud charges are increasing, and numerous
courts are stripping them of their veneer of immunity from
tort claims. Demands for a patients’ bill of rights are loud
on the land. In the words of my southern ancestors: good
riddance to bad rubbish. A pox on them all.
FUNCTIONAL OUTCOMES
Few things in medicine interest me less than feel-good
questionnaires in which patients are asked if some proce-
dure or other improved their perception of feeling good or
their perceived level of social functioning. I have always
thought such stuff properly belonged as the subject of some
obtuse doctoral thesis in social science. I continue to believe
that many, if not most, patient responses to health care
questionnaires are substantially preordained by how and by
whom the questions are asked. Certain outcome measures,
however, strike me as imminently important and realistic,
including such post–vascular surgery considerations as walk-
ing ability, independent or dependent living status, wound
healing including length of time devoted to care of surgical
complications incident to the index procedure, and the
need for subsequent surgical procedures. In my opinion, a
keen knowledge of such outcome measures should form an
essential component of surgical decision making, certainly
including the planning of all surgical procedures.
Consider for a moment a few lessons from history. In
the 1960s before there was no convention for describing
and publishing surgical results, most authors simply stated
how many patients did or did not have successful repairs at
randomly selected intervals after surgery. Then along came
the life-table method of reporting results, which was imme-
diately embraced by vascular surgeons. We became fasci-
nated by such intriguing concepts as interval and cumulative
patencies and began to display all our results in this fashion.
Concepts such as primary patency, primary assisted patency,
secondary patency, and limb salvage became everything. We
seemed to happily accept such absurdities as a 5-year
patency of some repair or another of 75% and a 5-year limb
salvage of 85%, but a 5-year patient survival of only 50%.
This of course introduced the important concepts of cen-
sured data, loss to follow-up, and the greatest contribution
an individual patient can make to a life table: dying with a
patent graft and a preserved limb.
It is abundantly clear that our evaluation of the overall
efficacy of numerous procedures has been measured by the
too limited concepts of patency and limb salvage and their
equivalents, without consideration of such critical informa-
tion as the quality of the patient’s life after surgery.
Although few will argue that in vascular surgery results are
everything, have we been considering the right results? We
were most surprised recently to learn in our practice that if
we defined optimal outcome after limb salvage surgery as
patent graft, limb salvage, preservation of preoperative liv-
ing status, prompt wound healing, and no need for addi-
tional surgery, only 15% of limb salvage patients enjoyed
such an optimal result. A similar although somewhat lesser
situation appears to pertain after aortic aneurysm repair.
In my opinion, we simply must begin to concern our-
selves with the total impact of our surgery on patients. For
example, if limb salvage surgery results in saving the limb
but restricts the patient to a nonambulatory nursing home
existence and the need for several additional leg opera-
tions, the patient may spend most of the rest of his life
dealing with the complications of and recovery from the
index operation and may consider the surgery an over-
whelming failure, whereas the surgeon, using the limited
concepts of patency and limb salvage, probably would
have recorded the procedure as an unqualified success.
It is probable that a significant number of patients, if
accurately and appropriately informed of the likelihood of
such an outcome, may prefer early amputation so they can get
on with the remainder of their limited life expectancy. A keen
and accurate knowledge of outcome expectations that go far
beyond the limited concepts of patency and limb salvage must
become an automatic and essential component of vascular
surgery decision making. An extension of this observation
concerns the recommendation of prophylactic surgery in cer-
tain patients. For example, a number of papers in recent years
have extolled the benefits of prophylactic carotid endarterec-
tomy in octogenarians. However, consider for a moment that
such a patient, according to national health statistics, has a life
expectancy of about 5 years and a net surgical stroke benefit
in the ACAS of 6% at 5 years. Compared with the risks and
expense of surgery, do these minuscule stroke prevention
benefits of 1% per year make any sense? Not to me they don’t.
On balance, I believe we have spent the last 40 years
in vascular surgery substantially learning what we can do.
I suspect we may spend the next 40 years learning what we
should do. We are just beginning to understand that in
many circumstances they may not be the same. For a cer-
tain number of aged and debilitated vascular patients, a
recommendation for no operation may be preferable to a
recommendation for surgery. In a number of fully
informed limb salvage patients, an early decision for limb
ablation may be preferable to persistent efforts at limb sal-
vage. In a similar manner for certain patients with an
abdominal aneurysm and prohibitive operative risks, the
decision for no intervention may well be the best decision,
the siren song of the endografters not withstanding.
The summary message is simple: There is more to vas-
cular surgery than patency, limb salvage, stroke-free exis-
tence, and procedural survival. We must all strive to develop
a more accurate and better informed understanding of the
full implications of surgery, an understanding predicated
both on a clear understanding of the natural history of the
untreated disease and a keen knowledge of the likely adverse
effects of a surgical procedure. In the final analysis, this
knowledge must be humanely combined with the realistic
expectations of the fully informed patient to permit the for-
mulation of optimal treatment recommendations. We must
strongly reject the role of being only a monofocal surgical
provider. We must be much more. In matters of vascular
disease, we must truly become the patient’s advocate,
notwithstanding the opinion of a number of nurses that this
is their exclusive, divinely appointed role.
RESIDENT EDUCATION AND CERTIFICATION
One of the most important professional responsibilities
we face is optimal education of our trainees. A monumental
step in the direction of controlling our own educational des-
tiny took place with the organization of the Association of
Program Directors in Vascular Surgery (APDVS). With the
official selection of directors of the ABS by the Joint Vascular
Council and the Program Directors and the de facto selec-
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tion of an APDVS representative to the Residency Review
Committee in Surgery, accomplished through the good
offices of the American College of Surgeons, we are now in
a position to have appropriately significant influence over our
own educational destiny. We all must be willing to devote
sufficient time and effort to the training of our residents.
Under no circumstances should these trainees be regarded as
merely the means to permit us to discharge our service obli-
gations. If we are not working continuously to improve the
residents’ educational experience, we are not doing our job.
I remain concerned that many of our residency programs
provide too much of too few things. For the many compo-
nents of vascular surgery not adequately represented in a par-
ticular residency, the program directors for years have been
mulling over a plan for a state of the art interactive Internet-
based educational program with the various residencies con-
tributing segments. I am pleased to note that under the able
leadership of Dr Blair Keagy this is about to occur.
For the present, inadequate exposure to the totality of
vascular surgery remains, in my opinion, one of the fore-
most problems facing vascular residency education. I sus-
pect many of you have been disappointed when serving as
an examiner for the ABS vascular certificate to note the nar-
row training of a number of supposedly fully trained vascu-
lar residents. This area must be continually reassessed. I pray
that Internet interactive education begins quickly and
achieves the desired success.
In considering vascular residency education, I would
like to say a word about the role of research training. Few
changes have been more laudable than the emphasis in
recent years on evidence-based medical practice. The
importance of scientifically valid clinical research has been
recognized by everyone. Opportunities abound for us to
address many of the vexing clinical problems facing vascu-
lar surgery by the design and conduct of careful clinical tri-
als. What a wonderful opportunity we have in our vascular
residency training programs to combine prospective clini-
cal research with resident education and patient care.
Residents so trained will be prepared to continue with a
career in academic vascular surgery or to write clinical
research reports from the perspective of clinical practice.
This brings me to the subject of basic science or bench
research in the training of vascular surgical residents. We
should strive to be the best at what we do. I observe that, in
the main, world-class bench research in vascular disease, as
well as in medicine in general, is being performed by indi-
viduals with a PhD, followed by years of focused postdoc-
toral training, who regularly work 60 to 70 hours per week
on their narrowly drawn bench projects. It makes no sense
to me to encourage a clinical vascular surgery resident to
dabble for 1 or 2 years in such an activity where they will
almost assuredly never be competitive, at least as long as they
wish to continue to be a clinical vascular surgeon. While they
no doubt learn a certain discipline and subliminal milieu
training, it is an inefficient method of instruction and ulti-
mately a nonproductive use of critical time. If the same time
and effort were devoted to clinical research training, the res-
ident would receive a research skill useful for a lifetime.
Training vascular surgical residents in cutting-edge basic
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research is simply perpetuation of the romantic fiction that it
is possible to do world-class clinical vascular surgery 4 days a
week and world-class bench research the remaining 1 day. It
won’t happen. The sooner we face this and devote this pre-
cious time to productive training in clinical research, the bet-
ter off our specialty will be.
Next, I would like to briefly address the issue of certifi-
cation in vascular surgery. I am sure you are all generally
familiar with the difficulty vascular surgery has historically
experienced in achieving recognition as a legitimate disci-
pline separate and distinct from general surgery. In my opin-
ion, the ABS, under the able stewardship of Dr Wallace
Ritchie, has made monumental progress in recent years in its
accommodation of vascular surgery. We currently have two
directors on the ABS and a sub-board in vascular surgery
with members appointed by the vascular societies and the
program directors. I am pleased to report that the sub-board
is indeed very much alive and functioning quite well. A
timely and well-written progress report describing the activ-
ities of the Sub-board in Vascular Surgery by Dr Clagett and
associates is available in the May 2000 issue of the Journal of
Vascular Surgery. I express appreciation to our board mem-
bers, Drs Clagett and LoGerfo, for their excellent efforts on
our behalf, and to Drs Towne, Whittemore, Calligaro, and
Zarins for their contributions as members of the sub-board.
As many of you know, the idea of exploring the forma-
tion of an American Board of Vascular Surgery was suggested
in 1996. While this may or may not have served as a stimulus
to facilitate negotiations between the ABS and vascular
surgery, I do believe this is an issue whose time has passed. I
have no desire to see vascular surgery separated from the cor-
pus of American surgery, as represented by the ABS and the
Residency Review Committee in Surgery. Keep in mind that
we are dependent on general surgery to provide our vascular
residents with their basic surgical training. We are obviously
not prepared to assume responsibility for all surgical training
of our residents beginning at medical school graduation.
With the impossibility of getting a new board of vascu-
lar surgery approved by the American Board of Medical
Specialties, either as a free-standing or conjoint board
notwithstanding, it is important to keep in mind that we do
not constitute a critical mass in the overall big picture. If we
were a board, we would be among the smallest, certifying
fewer than 100 trainees per year. It is most unlikely we
would be financially self-sufficient and would likely have to
rely on charitable contributions from diplomates for fiscal
survival. It is clear to me that our future lies with our
remaining firmly in the mainstream of American surgery.
We have achieved a great victory: the future is ours. The
amount of vascular surgery being performed by newly
trained general surgeons in practice is practically nil. The
observation that some vascular surgery continues to be per-
formed by cardiac surgeons does not, in my opinion, con-
stitute an insurmountable problem.
In summary, we are in the process of developing an excel-
lent relationship with the ABS, one that I do not wish to jeop-
ardize. I respectfully state my belief that it is time for the
nascent American Board of Vascular Surgery to exit, with our
thanks. Devotion of more time and money to this futile and
ultimately counterproductive endeavor appears quite foolish.
I urge everyone involved to put this divisive matter behind us
and devote future attention to more productive activities. I
am reminded of the famous quotation attributed to P. J.
O’Rourke: “Politics should be limited in its scope to war, pro-
tection of property, and the occasional precautionary behead-
ing of a member of the ruling class.” I hasten to add I have
not yet reached the stage of favoring the precautionary
beheading of anyone, although I retain this as an option.
ENTREPRENEURIALISM IN VASCULAR
SURGERY
I have saved until last the topic that has caused me the
most distress, namely, entrepreneurialism in medicine in
general and vascular surgery in particular. There is an
underlying basic truth that I suspect no one would dispute:
All treatment decisions must be predicated on what is per-
ceived as best for the patient, clearly NOT what appears
best for the doctor. Put another way, the assumption is that
physicians will put the interests of the patients above their
own. Everywhere one looks in medicine today, one
encounters devices and drugs in various stages of prepara-
tion for marketing. In recent years it has become clear that
a disturbing number of our colleagues who have routinely
participated in FDA-approved clinical trials of such prod-
ucts have had a major equity interest in the product.
Shouldn’t we all be offended by such revelations as,
for example, in the New York Times in the November 30,
1999, issue entitled “A Hidden Interest—A Special
Report; When Physicians Double as Entrepreneurs,”
which proceeded to take apart a number of entrepreneur-
ial interventional cardiologists for egregious conflicts of
interests, including naming names. It could have just as
well been about vascular surgeons. In January of this year
we were informed in the same New York Times that the
prestigious Institute for Human Gene Research at the
University of Pennsylvania Medical Center had its human
research activities abruptly closed by the FDA because of
concerns about patient safety and the lack of properly doc-
umented informed consents. Several days later we were
informed that the director of the institute had a major
equity interest in a start-up pharmaceutical firm that paid
the Gene Research Institute $5 million per year in return
for exclusive marketing rights for the director’s discover-
ies. Interestingly, in a press release on May 24, University
of Pennsylvania president, Dr Judith Rodin, announced,
after receiving a report prepared by a blue-ribbon review
panel, that all human research at the Institute for Human
Gene Therapy at the University of Pennsylvania was sum-
marily suspended.
An article in the May 4 issue of the New York Times
stated that a prominent New England angiogenesis
researcher is under investigation by the FDA for failure to
report a patient death in a gene-related experiment and
other serious protocol violations. We are also informed in
the same article that this investigation was funded by a pri-
vate Biomedical Research Company, of which the
researcher is cofounder and in which he has a major equity
interest, as does his hospital. The list goes on. In the May
13 edition, the Orange County Register stated that a
prominent University of Wisconsin orthopedic surgeon
and chief of the university’s organ procurement program
had been paid many thousands of dollars by for-profit
human tissue processing companies in return for sending
tissue their way. In my opinion, revelations such as these
should be regarded both as a great embarrassment and as a
call to action. If we do nothing to eliminate such egregious
conflicts of interest, we deserve the enmity of the public.
Consider for a moment just what pernicious influence
this threatens to have on our profession. Inherited wisdom
states that you can’t sit in two chairs with one ass. How
can you dispassionately perform and analyze clinical
research when you have a financial stake in a positive
result. Let’s face it, you can’t. As quoted in the New York
Times, Dr David Blumenthal, director of the Institute for
Health Policy at the Massachusetts General Hospital
recently stated: “I am not comfortable with scientists’
owning substantial equity in firms that are sponsoring
their clinical research. It creates a conflict of interest, and
the conflict is particularly difficult to justify in cases where
patients’ welfare may be affected.” This position is
poignantly emphasized in a powerful article and accompa-
nying editorial in the May 18, 2000, New England
Journal of Medicine by Bodenheimer and Angell, respec-
tively. Interestingly, in the May 26, 2000, Boston Globe we
are informed that Dean Joseph Martin of the Harvard
Medical School has just announced a new policy that med-
ical students and trainees must be specifically informed
when they are assigned to a project in which their mentor
has a financial interest. Good for Harvard!
A blue-ribbon panel was recently charged by Dr
Towne and me to formulate a policy to govern such con-
flicts of interest in our societies. Chaired by Dr Wayne
Johnston, the committee concluded and the joint council
agreed that full disclosure of financial interests must always
be made when one occupies a position of public trust,
such as speaker, panel member, session moderator, or
author of a paper in a peer-reviewed journal. Clearly, in
many circumstances this does not go far enough. I think
one should not hold himself out as a neutral or unbiased
scientist in the evaluation of any product in which he has
a financial interest, no matter how small. In these circum-
stances, the individual should voluntarily disqualify him-
self. Our new conflict of interest policy states that
annually, every member of all vascular society committees
and journal editors must complete a conflict of interest
form. At each council or committee meeting the chair
must request that all members disclose any potential con-
flict of interest with any items on the agenda.
It is important to note that potential conflicts of inter-
est exist if the individual or any family member has any of
the following relationships with biomedical companies,
device manufacturers, or pharmaceutical companies:
• paid consultancy, scientific advisory committee
membership, or lecturer during the preceding year
• officer, board member, trustee, owner or employee
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• owner of stock, stock options, or bonds (including
immediate family)
• patent held related to company activities
• investigator for the company, including holding
research grants
Consider for a moment some examples closer to
home. Some advocates of certain unproven endografts
currently abounding in vascular surgery have equity inter-
ests in the products. We are informed daily by a cacoph-
ony of manufacturers and surgical activists that the train is
leaving the station, and if we do not immediately embrace
all endovascular technologies, we risk being surgically dis-
enfranchised and left with no practice at all. We are told
there is no time for the performance of careful clinical
research to methodically evaluate the real utility of these
products. The fact that these endografts, as a group,
appear at a maximum to be only about 75% as good as
conventional surgically placed grafts seems to have escaped
the attention of a number of our enthusiastic colleagues.
It is most interesting to note that the vascular group at
Albany recently announced it has abandoned its method
of surgical aneurysmal exclusion because a small number
of these excluded aneurysms enlarged and some ruptured.
Is this not a perfect model of endograft-excluded
aneurysms being fed only by Type II endoleaks? What
should be our response when it finally becomes patently
obvious to even our endografting colleagues wearing
blinders that endografts are only about 75% or so as satis-
factory and durable as conventional surgically placed grafts
and additionally engender the absolute requirement for
lifetime imaging and occasional endovascular touch-ups? I
fear even an average plaintiffs attorney may be able to
bring this matter to a painful conclusion.
I continue to believe that one should do what one is
good at. In our case it is operative surgery, for which there
will assuredly be an increasing demand in view of the
remarkable aging of our population. We will never be as
facile with endovascular catheters as our fully trained inter-
ventional radiology colleagues, and we will never control
the patient volume of our cardiology colleagues. On the
other hand, neither of them can perform operative
surgery. I spent many years becoming a fully trained and
reasonably capable surgeon. Neither I nor anyone else will
become an expert catheter jockey in a few weeks or
months. I realize that my suggestion that vascular sur-
geons generally should concentrate on vascular surgery
brands me eternally as a reactionary throwback oblivious
to the marvels of the modern catheter and the obvious
corollary that we should immediately expel our competi-
tors and seize this wonderful technology as our own. So
be it. I cannot only stand the approbation but may take a
bit of perverse pride in it.
A further major problem in our entrepreneurial drug
and device field is the observation that important negative
information directly affecting the health of subjects in
experimental trials is in certain important areas being rou-
tinely delayed or obscured altogether by manufacturers.
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Research contracts appear to frequently prohibit publica-
tion of scientific information by trial participants without
the permission of the sponsoring company. Approval for
negative publications may simply not be forthcoming. This
has recently been called to our attention by Drs Rutherford
and Johnston in a blistering editorial in the May 2000 issue
of the Journal of Vascular Surgery. These gentlemen have
issued a clarion call urging us to demand timely adverse
professional notification from manufacturers. I pray we will
do so. Failure to disclose such information in a timely fash-
ion surely constitutes a major violation of public trust.
Other matters also cause concern. We are informed
that vascular centers are an ideal marketing strategy to
most efficiently disseminate our multifaceted and exquis-
itely modern services and products to the consuming pub-
lic. The opening of these vascular centers, of course, is best
accompanied by wide local press and TV coverage. In
activities such as these, we run the risk of becoming little
more than hucksters sharing a comfortable bed with
hordes of public relation and marketing experts. Other
areas demand attention. The old and critically important
concept of equipoise undergoes daily reevaluation as
investigators try to convince themselves that there really is
no clear difference between established treatment and the
potentially dangerous alternatives they wish to investigate,
any equity interest in the product or personal gain deriv-
ing from the investigation notwithstanding.
In response to all this I make a simple proposal. If you
have an equity interest in a product, do not purport to be
an unbiased scientific investigator of the product, because
such is impossible. Do not give public testimony about the
product and most assuredly do not publish purportedly
unbiased papers concerning the product. Additionally, in
my opinion, if you have an equity interest in an investiga-
tive product, you should not recruit your patients as
experimental subjects in any study evaluating the product.
The FDA has recently stated that experimental subjects
must be told if their physician has an equity interest in the
product under investigation. Clearly, I would go one step
further. If we do not eliminate or at the very least attempt
to control the pernicious entrepreneurialism gnawing at
the core of our professional activities, we risk giving up
our right to be considered a profession and risk being con-
sidered, and probably accurately, merely a business.
In summary, times are most assuredly changing. Many
things we presently do seem silly, some appear unthinking,
and a few appear reckless. While the risks are great, the
solutions seem obvious. I hope we have the courage to get
busy. I apologize if I have left any unoffended this morn-
ing although I hasten to add, in matters such as these,
offense is more often taken than given. We will all do well
to recall the words of John Hunter: “surgeons tend to for-
get they are not masters, but only servants.” It has been an
honor serving as your president. I wish us all well.
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